Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Rydén, L.
Right arrow Articles by Gadler, F.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Rydén, L.
Right arrow Articles by Gadler, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Pharmacological therapy for hypertrophic cardiomyopathy: what is the evidence for success?

L. Rydén* and F. Gadler

Department of Cardiology, Karolinska Hospital, Stockholm, Sweden

* Correspondence: Lars Rydén, MD, Professor of Cardiology, Department of Cardiology, Karolinska Hospital, S-171 76 Stockholm, Sweden.

Abstract

The available experience from studies of pharmacological treatment of patients with hypertrophic cardiomyopathy was mainly gained in selected patient samples, with severe symptoms or a complicated clinical setting. Moreover, most reports on drug efficacy are based on either acute mechanistic studies or non-controlled patient cohorts, which are usually rather restricted in numbers and followed for limited periods of time. Bearing in mind the symptomatic presentation of hypertrophic cardiomyopathy, which is sometimes highly variable and influenced to a degree by sympathetic arousal, it is understandable that a considerable placebo effect may occur when initiating any type of treatment. Considering the pathophysiology that underlies symptoms of hypertrophic cardiomyopathy, it is not surprising that the pharmacological agents that are most advocated are beta-blockers and calcium channel blockers - drugs that impact on several of the factors that are responsible for the symptoms. Other compounds that may be used include antiarrhythmic drugs, of which disopyramide - combining antiarrhythmic with negative inotropic properties - has attracted particular interest.

Key Words: Treatment • pharmacological • cardiomyopathy • hypertrophic • symptoms • evidence


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.